Developer docs
API playgroundTry for free, no card

Search company profiles

NBE-Therapeutics

Full company profile

uuid00027cy

Namestring
NBE-Therapeutics
Legal namestring
NBE-Therapeutics AG
Company typeenum
Private
Founded yearint
2012
Descriptiontext

NBE-Therapeutics AG is a Swiss biotech company founded in 2012 and headquartered in Basel, Switzerland, that develops next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors. Its integrated ADC platform combines four proprietary technologies: SMAC (sortase-enzyme mediated antibody conjugation) for site-specific, CMC-validated generation of homogeneous ADCs with precisely adjustable Drug-to-Antibody-Ratio; PNU-159682, a highly potent anthracycline derivative payload that induces immunogenic cell death and enables targeting of low-expressing antigens; Transpo-mAb mammalian cell display for functional antibody discovery using DNA transposition; and iADC, an immune-oncology ADC modality designed to drive durable anti-tumor immunity. The company maintains a pipeline of ADC product candidates targeting solid tumors at various preclinical stages of development.

Since December 2020, NBE-Therapeutics has operated as a wholly owned subsidiary of Boehringer Ingelheim following an acquisition valued at approximately $1.4 billion. Its business model is pre-commercial: the company is financed by its parent and prior venture investors (including Boehringer Ingelheim Venture Fund, PPF Group, and Novo Holdings, which together provided over $65 million in venture funding and $4 million in non-dilutive grants), and it generates revenue through R&D execution and pipeline development for the broader Boehringer Ingelheim ADC portfolio rather than direct product sales. A new NBE Therapeutics R&D center in Basel was announced in April 2025, and a COO was appointed in September 2025, both signals of continued investment by the parent.

Short descriptiontext

NBE-Therapeutics AG is a Basel-based biotech that develops next-generation antibody-drug conjugates (ADCs) targeting solid tumors for cancer patients, operating as a wholly owned subsidiary of Boehringer Ingelheim since its December 2020 acquisition.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, oncology therapeutics development, cancer immunotherapy, antibody conjugation technology, solid tumor treatments
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antibody-Drug Conjugates (Oncology Biopharmaceuticals)
No data
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NBE-Therapeutics is a Swiss clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for targeted treatment of solid tumor cancers. Its offering centers on four proprietary platform technologies — SMAC-Technology™ for site-specific conjugation, a PNU anthracycline payload, Transpo-mAb™ Display for antibody discovery, and an immune-oncology ADC (iADC) approach — used to progress a pipeline of ADC therapeutic candidates.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

NBE-Therapeutics is a privately-owned Swiss biotech company (acquired by Boehringer Ingelheim in December 2020) that develops next-generation antibody-drug conjugates (ADCs) for oncology treatment. The company operates an integrated ADC platform comprising four core proprietary technologies: SMAC-Technology™ for site-specific conjugation, PNU Anthracycline Payload (PNU-159682) for highly potent payload delivery, Transpo-mAb™ Display for antibody discovery, and iADC for immune-oncology effects. These technologies work together to enable the development of targeted cancer therapies that combine antibody selectivity with small molecule efficacy, with a pipeline of ADC candidates targeting solid tumors in various stages of clinical development.

Product and service1 record
1SMAC-Technology™
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-01
Description

Boehringer Ingelheim acquired NBE-Therapeutics in December 2020, making NBE a wholly-owned subsidiary. Boehringer Ingelheim Venture Fund (BIVF) had previously been a lead investor prior to the acquisition. The acquisition strengthens Boehringer Ingelheim's antibody-drug conjugate portfolio. A new NBE Therapeutics R&D center was established in Basel in 2025.

nbe-therapeutics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss-based clinical-stage biotech developing antibody-drug conjugates for hematologic and solid tumors. Highly comparable as a similarly-sized ADC-focused company with proprietary payload and conjugation technologies targeting oncology.

TypeDirect peer
Description

Clinical-stage biotech developing next-generation ADCs with proprietary payload platforms (Dolasynthen, Immunosynthen) targeting solid tumors. Directly comparable ADC platform approach with differentiated conjugation and immune-engaging payload strategies similar to NBE's iADC.

TypeDirect peer
Description

German clinical-stage biotech developing ADCs based on proprietary amanitin payload chemistry for solid tumors. Comparable as an ADC platform company with novel payload technology addressing challenging target space, similar to NBE's PNU strategy.

TypeEmerging player
Description

German biotech developing next-generation ADCs with novel linker and conjugation chemistries (P5 conjugation technology) for solid tumors. Comparable emerging ADC platform player with proprietary conjugation technology analogous to NBE's SMAC approach.

TypeEmerging player
Description

Clinical-stage biotech developing immune-stimulating ADCs (Boltbody ISACs) that combine tumor-targeting with immune activation. Closely comparable mechanism-of-action concept to NBE's iADC platform — combining ADC delivery with anti-tumor immune response.

TypeEmerging player
Description

Clinical-stage biotech developing ADC and immune-engaging antibody therapeutics for solid tumors. Comparable as a focused ADC platform company building a pipeline around proprietary antibody-drug conjugate technologies in oncology.

TypeDirect peer
Description

Clinical-stage biotech with proprietary cell-free protein synthesis platform enabling site-specific conjugation and ADC development. Comparable ADC platform company with proprietary discovery and conjugation technology targeting solid tumors.

TypeEmerging player
Description

Clinical-stage biotech developing bicyclic peptide conjugates (Bicycles) and toxin conjugates for oncology. Comparable as an emerging targeted-conjugate company using novel chemistry approaches to address solid tumor targets with payload delivery.

TypeBroad incumbent
Description

Global pharmaceutical company and ADC leader (Enhertu, Datroway) with industry-leading DXd payload platform. Comparable as the dominant commercial-stage ADC incumbent competing for the same solid tumor opportunities NBE targets.

TypeBroad incumbent
Description

Pfizer's oncology franchise (including acquired Seagen) is a leading ADC commercial player (Adcetris, Padcev, Tukysa). Comparable as a broad incumbent with established ADC commercial infrastructure and pipeline that NBE ultimately leverages through Boehringer Ingelheim.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NBE-Therapeutics

Antibody-Drug Conjugates (Oncology Biopharmaceuticals)nbe-therapeutics.com

NBE-Therapeutics AG is a Basel-based biotech that develops next-generation antibody-drug conjugates (ADCs) targeting solid tumors for cancer patients, operating as a wholly owned subsidiary of Boehringer Ingelheim since its December 2020 acquisition.

What NBE-Therapeutics does

NBE-Therapeutics AG is a Swiss biotech company founded in 2012 and headquartered in Basel, Switzerland, that develops next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors. Its integrated ADC platform combines four proprietary technologies: SMAC (sortase-enzyme mediated antibody conjugation) for site-specific, CMC-validated generation of homogeneous ADCs with precisely adjustable Drug-to-Antibody-Ratio; PNU-159682, a highly potent anthracycline derivative payload that induces immunogenic cell death and enables targeting of low-expressing antigens; Transpo-mAb mammalian cell display for functional antibody discovery using DNA transposition; and iADC, an immune-oncology ADC modality designed to drive durable anti-tumor immunity. The company maintains a pipeline of ADC product candidates targeting solid tumors at various preclinical stages of development.

Since December 2020, NBE-Therapeutics has operated as a wholly owned subsidiary of Boehringer Ingelheim following an acquisition valued at approximately $1.4 billion. Its business model is pre-commercial: the company is financed by its parent and prior venture investors (including Boehringer Ingelheim Venture Fund, PPF Group, and Novo Holdings, which together provided over $65 million in venture funding and $4 million in non-dilutive grants), and it generates revenue through R&D execution and pipeline development for the broader Boehringer Ingelheim ADC portfolio rather than direct product sales. A new NBE Therapeutics R&D center in Basel was announced in April 2025, and a COO was appointed in September 2025, both signals of continued investment by the parent.

NBE-Therapeutics firmographics

Firmographics
Name
NBE-Therapeutics
Legal name
NBE-Therapeutics AG
Website
https://nbe-therapeutics.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
NBE-Therapeutics AG is a Basel-based biotech that develops next-generation antibody-drug conjugates (ADCs) targeting solid tumors for cancer patients, operating as a wholly owned subsidiary of Boehringer Ingelheim since its December 2020 acquisition.
Ownership category
akta.pro rank

NBE-Therapeutics industry classification

Industry
Product category
Antibody-Drug Conjugates (Oncology Biopharmaceuticals)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody-drug conjugates
  • Oncology therapeutics development
  • Cancer immunotherapy
  • Antibody conjugation technology
  • Solid tumor treatments

Where NBE-Therapeutics is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

NBE-Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Distribution channels1 record

Marketing channels4 records

NBE-Therapeutics product offering

Product offering

Core offering

NBE-Therapeutics is a Swiss clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for targeted treatment of solid tumor cancers. Its offering centers on four proprietary platform technologies — SMAC-Technology™ for site-specific conjugation, a PNU anthracycline payload, Transpo-mAb™ Display for antibody discovery, and an immune-oncology ADC (iADC) approach — used to progress a pipeline of ADC therapeutic candidates.

Product overview

NBE-Therapeutics is a privately-owned Swiss biotech company (acquired by Boehringer Ingelheim in December 2020) that develops next-generation antibody-drug conjugates (ADCs) for oncology treatment. The company operates an integrated ADC platform comprising four core proprietary technologies: SMAC-Technology™ for site-specific conjugation, PNU Anthracycline Payload (PNU-159682) for highly potent payload delivery, Transpo-mAb™ Display for antibody discovery, and iADC for immune-oncology effects. These technologies work together to enable the development of targeted cancer therapies that combine antibody selectivity with small molecule efficacy, with a pipeline of ADC candidates targeting solid tumors in various stages of clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • SMAC-Technology™

Companies that use NBE-Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

NBE-Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NBE-Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Boehringer IngelheimcoreStrategic or Co-development Partner · 1 December 2020Boehringer Ingelheim acquired NBE-Therapeutics in December 2020, making NBE a wholly-owned subsidiary. Boehringer Ingelheim Venture Fund (BIVF) had previously been a lead investor prior to the acquisition. The acquisition strengthens Boehringer Ingelheim's antibody-drug conjugate portfolio. A new NBE Therapeutics R&D center was established in Basel in 2025.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

NBE-Therapeutics competitors and assessment

Company assessment

Direct peers

  • ADC Therapeutics: Swiss-based clinical-stage biotech developing antibody-drug conjugates for hematologic and solid tumors. Highly comparable as a similarly-sized ADC-focused company with proprietary payload and conjugation technologies targeting oncology.
  • Mersana Therapeutics: Clinical-stage biotech developing next-generation ADCs with proprietary payload platforms (Dolasynthen, Immunosynthen) targeting solid tumors. Directly comparable ADC platform approach with differentiated conjugation and immune-engaging payload strategies similar to NBE's iADC.
  • Heidelberg Pharma: German clinical-stage biotech developing ADCs based on proprietary amanitin payload chemistry for solid tumors. Comparable as an ADC platform company with novel payload technology addressing challenging target space, similar to NBE's PNU strategy.
  • Sutro Biopharma: Clinical-stage biotech with proprietary cell-free protein synthesis platform enabling site-specific conjugation and ADC development. Comparable ADC platform company with proprietary discovery and conjugation technology targeting solid tumors.

Emerging players

  • Tubulis: German biotech developing next-generation ADCs with novel linker and conjugation chemistries (P5 conjugation technology) for solid tumors. Comparable emerging ADC platform player with proprietary conjugation technology analogous to NBE's SMAC approach.
  • Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating ADCs (Boltbody ISACs) that combine tumor-targeting with immune activation. Closely comparable mechanism-of-action concept to NBE's iADC platform — combining ADC delivery with anti-tumor immune response.
  • Pyxis Oncology: Clinical-stage biotech developing ADC and immune-engaging antibody therapeutics for solid tumors. Comparable as a focused ADC platform company building a pipeline around proprietary antibody-drug conjugate technologies in oncology.
  • Bicycle Therapeutics: Clinical-stage biotech developing bicyclic peptide conjugates (Bicycles) and toxin conjugates for oncology. Comparable as an emerging targeted-conjugate company using novel chemistry approaches to address solid tumor targets with payload delivery.

Broad incumbents

  • Daiichi Sankyo: Global pharmaceutical company and ADC leader (Enhertu, Datroway) with industry-leading DXd payload platform. Comparable as the dominant commercial-stage ADC incumbent competing for the same solid tumor opportunities NBE targets.
  • Pfizer (Seagen): Pfizer's oncology franchise (including acquired Seagen) is a leading ADC commercial player (Adcetris, Padcev, Tukysa). Comparable as a broad incumbent with established ADC commercial infrastructure and pipeline that NBE ultimately leverages through Boehringer Ingelheim.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

NBE-Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NBE-Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

NBE-Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NBE-Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NBE-Therapeutics

What does NBE-Therapeutics do?

NBE-Therapeutics is a Swiss clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for targeted treatment of solid tumor cancers. Its offering centers on four proprietary platform technologies — SMAC-Technology™ for site-specific conjugation, a PNU anthracycline payload, Transpo-mAb™ Display for antibody discovery, and an immune-oncology ADC (iADC) approach — used to progress a pipeline of ADC therapeutic candidates.

Is NBE-Therapeutics a public or private company?

NBE-Therapeutics is a private company. It is classified as corporate owned and is currently operating.

When was NBE-Therapeutics founded?

NBE-Therapeutics was founded in 2012. It employs 11 to 50 people.

Where is NBE-Therapeutics based?

NBE-Therapeutics is headquartered in Basel, Switzerland, in the Europe region.

Who are NBE-Therapeutics's main competitors?

Direct peers on record are ADC Therapeutics, Mersana Therapeutics, Heidelberg Pharma and Sutro Biopharma. Emerging players are Tubulis, Bolt Biotherapeutics, Pyxis Oncology and Bicycle Therapeutics. Broad incumbents are Daiichi Sankyo and Pfizer (Seagen).

Does NBE-Therapeutics have an API?

No public API is recorded for NBE-Therapeutics.

What industry is NBE-Therapeutics in?

NBE-Therapeutics's product category is Antibody-Drug Conjugates (Oncology Biopharmaceuticals). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireBoehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in BaselNBE Therapeutics, a Boehringer Ingelheim subsidiary, opened a new antibody-drug conjugate R&D facility in Basel, Switzerland. The investment of CHF 27 million will support next-generation ADC development, with the building meeting Swiss sustainability standards and housing about 50 scientists.EuropaWireBasel Unveils Cutting-Edge R&D Hub Fueling Next-Gen Cancer Therapy InnovationsNBE Therapeutics, a Boehringer Ingelheim subsidiary, inaugurated a CHF 27 million antibody-drug conjugate R&D facility in Basel. The 1,826 m² building meets Swiss sustainability standards and will host about 50 scientists. The investment follows a licensing deal with Synaffix B.V. and complements a new Vienna center.GlobeNewswireBoehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in BaselNBE Therapeutics, a Boehringer Ingelheim subsidiary, opened a new antibody-drug conjugate R&D facility in Basel, Switzerland. The investment totals CHF 27 million over several years and will support next-generation ADC development. The facility meets Swiss sustainability standards and will house about 50 scientists.YahooBoehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in BaselNBE Therapeutics, a Boehringer Ingelheim subsidiary, opened a new antibody-drug conjugate R&D facility in Basel, Switzerland. The investment totals CHF 27 million over several years, supporting the company's oncology pipeline. The facility aims to accelerate next-generation ADC development for cancer treatments.Business & FinancialBoehringer Ingelheim Strengthens Antibody-Drug Conjugate Portfolio With New NBE Therapeutics R&D Center In BaselNBE Therapeutics, a Boehringer Ingelheim subsidiary, opened a new antibody-drug conjugate R&D facility in Basel, Switzerland. The investment of CHF 27 million over several years will support next-generation ADC development. The building meets Swiss sustainability standards and will house about 50 scientists.YahooBoehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in BaselNBE Therapeutics, a Boehringer Ingelheim subsidiary, opened a new antibody-drug conjugate R&D facility in Basel, Switzerland. The investment totals CHF 27 million over several years and will support next-generation ADC development. The building meets Swiss sustainability standards and will house about 50 scientists.Basel Area Business & InnovationThe 6 stages of a startup (and how to master each).The article outlines the six developmental stages of a startup, ranging from pre-seed ideation to exit strategies such as acquisitions or IPOs. It utilizes specific case studies, including AERA Health, Lyfegen, and Boehringer Ingelheim's acquisition of NBE-Therapeutics, to illustrate funding milestones and strategic challenges at each phase.GlobeNewswireAcquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF GroupPPF Group signed a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim for up to €1.18 billion, including upfront and milestone payments. NBE-Therapeutics will remain in Basel and continue its partnership with PPF-owned SOTIO on two ADC programs. SOTIO expects to advance SO-N102 into clinical trials by end of 2021.startupticker.chNBE Therapeutics makes a €1.18 billion exitBoehringer Ingelheim agreed to acquire all shares of Swiss biotech NBE Therapeutics for €1.18 billion, including contingent milestones. The deal adds NBE's iADC platform to Boehringer's oncology portfolio, with closing expected in Q1 2021.BenzingaMerger Thursday: Gilead Buys German Drug Company, Aytu-Neos All-Stock Deal, Boehringer Picks Up NBE-Therapeutics - Aytu BioPharma (NASDAQ:AYTU), Gilead Sciences (NASDAQ:GILD)Gilead agreed to acquire German biotech MYR for $1.39 billion in cash plus milestone payments, Aytu will acquire Neos Therapeutics in an all-stock deal valued at $44.9 million, and Boehringer Ingelheim agreed to buy Swiss biotech NBE-Therapeutics for $1.43 billion. The deals aim to expand Gilead's HDV therapy, Aytu's pediatric ADHD portfolio, and Boehringer's ADC platform.